Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16680706 | 0.90 | SMN1; SMN2 (0.48) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL5085765 | 0.88 | SMN1; SMN2 (0.50) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL844472 | 0.88 | SMN1; SMN2 (0.57) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL14040614 | 0.88 | SMN1; SMN2 (0.57) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL2320404 | 0.87 | FAAH (0.59) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL4097623 | 0.87 | SMN1; SMN2 (0.48) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL5181827 | 0.87 | KMT2A (0.53) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL4265545 | 0.87 | SMN1; SMN2 (0.50) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL4850183 | 0.87 | CTSA (0.48) | FAAHSMN1; SMN2MAPK1PRNPNPSR1 | |
| SCHEMBL16680263 | 0.86 | ITGB3 (0.45) | FAAHSMN1; SMN2NPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234982-A1 | SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080523-A1 | SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008101840-A1 | COMBINATION OF ERLOTINIB AND MEK-INHIBITORS FOR INHIBITING PROLIFERATION OF TUMOR CELLS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| EP-1791837-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. Hoffmann-Roche AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006029862-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |